YMAB - Y-mAbs Therapeutics, Inc.
IEX Last Trade
13.595
0 0%
Share volume: 0
Last Updated: Fri 20 Dec 2024 09:18:12 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.46%
PREVIOUS CLOSE
CHG
CHG%
$13.60
-5.10
0.60%
View ratios
Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
---|---|---|---|---|---|---|---|---|---|
Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
Report Date | 2022-08-08 | 2022-11-07 | 2023-03-30 | 2023-05-08 | 2023-08-10 | 2023-11-13 | 2024-02-29 | 2024-05-07 | |
Cash flow financing | 0.000 | 52.000 K | 0.000 | 0.000 | 0.000 | 0.000 | 100.000 K | 588.000 K | |
Other financing cash flows | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Cash flow | -23.100 M | -19.235 M | -8.661 M | -13.124 M | -4.734 M | -1.338 M | -8.036 M | -3.477 M | |
Net income | -41.131 M | -27.526 M | 1.157 M | -6.390 M | -6.302 M | -7.747 M | -988.000 K | -6.629 M | |
Depreciation | 188.000 K | 226.000 K | 230.000 K | 182.000 K | 224.000 K | 168.000 K | 161.000 K | 159.000 K | |
Changes in inventories | 6.794 M | 6.242 M | 6.702 M | 8.945 M | 5.187 M | 7.113 M | 5.065 M | 8.448 M | |
Changes in receivables | 7.208 M | 9.251 M | 12.531 M | 18.702 M | 19.118 M | 18.874 M | 22.454 M | 20.588 M | |
Investing Cashflow | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Net Borrowings | -137.524 M | -115.532 M | -109.447 M | -94.875 M | -90.234 M | -87.250 M | -82.173 M | -78.050 M | |
Investing Activity Other | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Dividends Paid | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Exchange Rate Effect | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Capital Expenditures | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Cash Change | 133.665 M | 114.526 M | 105.762 M | 92.629 M | 87.909 M | 86.571 M | 78.637 M | 75.749 M |